0006-4971 I91 J7708-OO20$3.00/0 was significantly elevated in 83.5% of the patients with active disease, and for each active disease group it was significantly greater [P < .0001) than in the control. Thus, the high circulating CSF-1 concentration was not associated with a particular malignant phenotype or MDS subtype, but did correlate with the disease activity of both NHL and HD, and the tumor burden in MM, AML, and CLL. There was no correlation of the CSF-1 level with total counts of monocytes or neutrophils in patients with MDS or other malignancies. The cellular basis for the elevated circulating CSF-1 was not investigated. However, the results are consistent with the possibility that the premalignant or malignant cells themselves produce CSF-1 or regulate its production by normal cells. o 1991 by The American Society of Hematology.
ment.I6 In addition, several different malignant cell types have been reported to express CSF-1 transcripts, including primary cells such as acute myelogenous leukemia (Ah4L) blasts,'9 cells in diffuse large-cell lymphoma, lymphoblastic leukemia and myeloma:' and cell lines from Hodglun's disease (HD)" and multiple myeloma (MM)." Other tumor cell lines releasing CSF-1 include pancreatic carcinoma? and adenocarcinomas of lung, breast, ovary, and endom e t r i~m . '~,~~ However, the clinical significance of CSF-1 in malignancy is unknown.
Although CSF-1 is detectable in circulating blood, the mechanisms regulating its physiologic levels in humans are still poorly understood. In mice, the CSF-1 level is thought to be regulated in part by a feedback control mechanismz5 whereby its increased concentration stimulates proliferation of macrophage precursors and production of mature macrophages that, in turn, clear CSF-1 from the circulation through CSF-1 receptor-mediated endocytosis and degradation.
Although a reliable specific radioimmunoassay for CSF-1 was developed more than a decade ago,132 the changes in circulating CSF-1 in various pathologic states have not been extensively studied. There has been a preliminary report of increased CSF-1 production in response to infections and severe neutropenia,z and we have noted elevation of CSF-1 levels in patients with certain malignant disorder^.^^,^ In the present work, which stemmed from our observation that the increases in these patients appeared to correlate with the biologic aggressiveness of the neoplasms, we determined CSF-1 concentrations in sera from 316 patients with premalignant and malignant hematologic disorders and sought to correlate these with the type and status of the disease. Criteria for entry into the study included freedom from clinically evident infections (bacterial, viral, fungal) or other systemic disease, normal kidney function, and no previous treatment with recombinant cytokines. The status of the disease was evaluated on the day the blood sample was withdrawn, by complete medical history and physical examination, complete blood count and differential leukocyte count, serum chemistry tests and radiologic studies, and with computed tomography (CT) scanning and biopsy of bone marrow or lymph node(s) where requisite to diagnosis. The patients were subdivided into groups according to the type of their disease, status of the disease and treatment status. 'Active' disease in our study applies to (1) newly diagnosed, relapsed, progressive disease, and (2) disease in the plateau phase as in MM. Only patients in complete remission according to accepted definitions for their diseases are regarded as "in remission" in this study. Treatment status was defined as: (1) "No therapy" indicates newly diagnosed NHL or patients with persistent disease who were never treated (eg, some cases of NHL of low-grade malignancy, or CLL). In HD, apart from newly diagnosed cases, new cases of recurrent disease were included. In MM, patients who had newly diagnosed disease or had been untreated for 3 months to 2 years and were in the plateau phase of their disease were included in this group. (2) "Off therapy" defines patients whose disease was in complete remission at the time of study and were not receiving any therapy. (3) "On therapy" defines patients who were then receiving combination therapy or single agents for their disease.
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Control blood samples were obtained from 64 healthy volunteer donors attending the Canadian Red Cross Blood Transfusion Centre or residents in seniors' homes.
The criteria for diagnosis of MDS were those of the FrenchAmerican-British (FAB) cooperative group.29 Withdrawal of blood samples was timed to coincide with aspiration of bone marrow for the purpose of diagnosis. None of the patients was receiving anything other than supportive therapy. Diagnosis of AML was made according to the FAB classification"; three of 10 new patients were studied again when the disease was in remission, one patient was already in remission, and one was in first relapse. Only two patients with AML (one in relapse and one in remission) were receiving chemotherapy at the time of study. Six of the seven patients with CML were on chemotherapy (hydroxyurea or busulfan); one was in blastic transformation, one in remission, two in accelerated phase, and three in chronic phase. Diagnoses of NHL were made according to the working formulation (WF) classification" (Table 1) . Histologic definition of H D was based on the Rye clas~ification.~~ MM was defined by the National Cancer Institute (NC1)-(C) group ~riteria.3~ 'Active' MM included newly diagnosed, relapsing, progressive disease, and MM in the plateau phase. "On therapy" MM patients were receiving combination therapy with Melphalan, vincristine/adriamycin/dexamethasone (VAD), or cyclophosphamide/prednisone, according to NCI-(C) protocols. Eight patients with CLL had increased lymphocytosis only and 13 had additional enlargement of lymph nodes and spleen, 12 patients were receiving chlorambucil, with or without prednisone, when the samples were taken.
Circulating CSF-1 was measured by a modified*' radioimmunoassay,2 except that purified recombinant human CSF-1 (8 x lo7 units (U)/mg protein), a gift from Cetus Corporation (Emeryville, CA), iodinated as de~cribed'~ was used as the source of radiolabeled growth factor. This assay specifically detects biologically active CSF-1 in the range of 1 to 300 U/tube. To avoid interference from other blood proteins, serum and plasma samples were diluted at least 10-fold before assay. One unit of CSF-1 is defined by comparison with a stable standard reference preparation's and represents 0.44 fmol or 12 pg protein. As shown in Fig 1, for blood samples from 27 patients, there was a close correlation (I' = .739, P < .01, two-tailed) between CSF-1 concentrations determined in serum and plasma, indicating that either serum or plasma could be used. The majority of samples assayed in the present study were serum samples.
Calculations were performed on a microcomputer (Macintosh SE; Apple Computer, Cupertino, CA) with use of a standard statistical package. The Mann-Whitney U-test and the Student's t-test were appropriate, and Pearson correlations were used. Differences were considered significant at P < .05. All values were expressed as the means * SD; CSF-1 concentrations were considered elevated when values exceeded 2 SD above the mean normal value.
CSF-I assay.
Stafistrcalmethods.
RESULTS
Serum CSF-1 concentrations for the 64 healthy adult control subjects (35 men, 29 women) were normally distributed in the range of 144 to 700 U/mL. The mean concentration was 372 % 111 U/mL (Fig 2) . The age range was 18 to 76 years (mean
CSF-I levels in normal (control) subjects.
For personal use only. on September 22, 2017 . by guest www.bloodjournal.org From 39 5 14) , and there was no relation between circulating CSF-1 concentration and age or sex (data not shown).
CSF-1 levels in preleukemia and myeloid leukemia. Serum CSF-1 concentrations were grouped by FAB subtype of MDS (Fig 2, Table 2 ). The mean CSF-1 concentration in MDS was higher (P < .0001) than for normal controls, with no significant intergroup differences. The mean total counts of white blood cells (WBC), neutrophils, and monocytes, respectively, for the 75 patients with MDS were: 6. concentration and circulating levels of these cells (Fig 3) or number of bone marrow blasts in MDS (data not shown). Elevated levels of CSF-1 were observed in all AML patients (Fig 2, Table 2 ), and the CSF-1 level correlated with the total leukocyte (r' = .616, P < .01) and blast cell (r' = S64, P < .Ol) concentrations in peripheral blood (Fig   4) . Although numbers of patients in the FAB subgroups were small, CSF-1 values for those with M5 and M4 AML subtypes that previously have been shown to express the highest CSF-1R levels,36 were relatively high (means 1,671 and 1,575 U/mL, respectively). In three (of a total of four) AML patients restudied during remission of their disease, CSF-1 values were lower (mean 820 U/mL) than initially For 
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(mean 1,457 U/mL) (Fig 2) , but the difference was not statistically significant. In CML the serum CSF-1 concentration was significantly increased in all patients. The lowest value was in a sample from a patient in complete hematologic remission (Fig 2,  Table 2 ). No significant correlations could be established in CML between CSF-1 concentration and total leukocyte or blast cell count. However, most of the patients were on therapy.
Serum concentrations of CSF-1 were increased in 62% of all patients with NHL and in 85% of those with active disease (Fig 2) . Patients with active NHL had significantly higher levels (P < .0001) than those in remission, suggesting a relationship between CSF-1 level and disease activity ( Table 3) . Moreover, the values were within normal range in 30% of patients with low-grade malignancy but only 6.6% of those with intermediate-grade malignancy, suggesting a relationship between CSF-1 production and aggressiveness of the disease. The mean CSF-1 values were similar in cases of newly diagnosed and with persistent untreated disease and in patients undergoing chemotherapy ( Table 3) . Mean WBC counts in untreated and treated groups of patients were 4.2 & 2 x 109/L and 5.8 2 2.8 x 109/L, respectively; no correlation was found between CSF-1 values and total leukocyte, monocyte, or neutrophil counts for these groups CSF-1 levels in lymphoid malignancies. (data not shown). In remission, the CSF-1 levels returned to norm31 values in NHL of high-grade malignancy; however, in low and intermediate grades, this was not the case. In HD, serum CSF-1 was elevated in 84% of patients with active disease but only 29% of those in remission (Fig 2) . As in the case of NHL patients, patients with active HD had significantly higher levels (P = .0001) than those in remission, and chemotherapy had no effect on mean CSF-1 values ( Table 3) . No correlations of the latter were found with WBC, leukocyte, monocyte, or neutrophil counts.
CSF-1 concentrations were elevated in about 50% of patients with MM (Fig 2) . CSF-1 levels in samples obtained from patients with active disease and in remission were not statistically different (Table 3) ; however, they were significantly greater (P < .05) in patients with high pz microglobulin levels (4 to 6 mg/L and > 6 mg/L) than in those with lower levels ( < 4 mg/L) ( Table 4) , indicating a correlation with tumor burden in MM. Conversely, the three cases of benign MGUS had normal CSF-1 levels (Fig 2) . No relationship was found in MM between CSF-1 levels and M-protein levels.
Nineteen of 21 patients with CLL possessed elevated circulating CSF-1 levels (Fig 2) . The mean CSF-1 concentration was significantly lower in the eight patients with increased lymphopoiesis only than in those with additional enlargement of lymph nodes and/or spleen (P = .0016). CSF-1 values did not correlate with the WBC or lymphocyte count in CLL (data not shown).
DISCUSSION
Our finding of increased CSF-1 levels in the peripheral blood of patients with preleukemia, myeloid leukemia, and lymphoid malignancies, together with the reported" increases in such disorders as polycythemia vera (PR), essential thrombocythemia (ET), and myeloid metaplasia (MyM), permits the conclusion that the concentration of CSF-1 in peripheral blood is increased in most patients with a hematologic malignancy or premalignant hematologic state. This conclusion implies that the increase is not specific to any one malignant or premalignant phenotype. Moreover, the high CSF-1 levels correlated with activity of the disease (NHL, HD) or the degree of tumor burden (AML, MM, CLL), but not with total counts of monocytes or neutrophils in the peripheral blood.
The first hypothesis we considered to explain this response was that the increased concentration of CSF-1 could For personal use only. on September 22, 2017 . by guest www.bloodjournal.org From *In all cases P for no therapy (or off therapy) versus on therapy was NS or NE. tNewly diagnosed, or untreated persistent disease. *Newly diagnosed, or in relapse. §Newly diagnosed, or in plateau phase and off therapy for 3 months to 2 years.
reflect its increased production by activated normal cells. Synthesis of CSF-1 by activated mononuclear phagocytes could increase during inflammatory or immune responses such as direct interactions with organisms and/or antigen, with activated T lymphocytes, or with products of the activation of the complement and coagulation systems, as well as during the processing and presentation of immunologically active molecules to the T lymphocyte. Activated mononuclear phagocytes secrete other cytokines (granulocyte-macrophage CSF [GM-CSF], interleukin-1 [IL-11, IL-3, tumor necrosis factor [TNF], interferons) that not only enhance secretion of CSF-1 by mononuclear phagocytes but also activate other cells to produce these cytokines and CSF-l?','* Furthermore, evidence is emerging that certain cytokines act in s y n e r g~?~~~ Thus, there are many events leading to mononuclear phagocyte activation in patients that could lead to increased circulating CSF-I. Because of the well-documented elevation of circulating CSF-1 by bacterial endotoxin in mice, we have very thoroughly excluded from this study patients with any symptom of inflammation. However, undetectable subclinical infections, in addition to the reactions outlined above that accompany tumor-cell recognition, could contribute to increased production of CSF-1. The number of activated monocytes and macrophages appears to increase in some myeloproliferative disorders.
For This increase is accompanied by a high level of circulating CSF-1 in patients with PRV, ET, and MYM.'~ In the present study, levels were also elevated in the other myeloproliferative disorder, CML. These results could either reflect production of CSF-1 by mononuclear phagocytes or the CSF-1-stimulated production of monocytes/macrophages and synthesis of CSF-1 by other cells. However, we observed a similar increase in CSF-1 in refractory anemias also, as well as lymphoid malignancies not typified by expanded populations of normal monocytes/macrophages. Indeed, in patients with myelodysplastic syndromes, leukemia, lymphoma, and other malignancies, the function of normal lymphocytes and macrophages may be impaired4145 (eg, depressed cytotoxicity of monocytes, and abnormal chemotactic responsiveness of monocytes). Thus, at least in these conditions, production of CSF-1 by mononuclear phagocytes seems unlikely and an elevated CSF-1 level does not appear to have stimulated production of mononuclear phagocytes. Furthermore, in all of the examined conditions there was no correlation between CSF-1 and the concentration of any particular type of circulating leukocyte. The second hypothesis that might explain the increase in CSF-1 in these premabgnant and malignant conditions is that autocrine or paracrine loops contribute to the stimulation of neoplastic growth. This possibility has been investigated for CSF-1 and other cytokines, especially in leukemia19,46,47 and myeloma.48 In human myeloid Ieukemia cells, CSF-1 mRNA and c-fms genes are expressed simultaneously and stably in some cases,19 indicating that the growth of such cells may be enhanced through an autocrine mechanism. Rearrangements of the CSF-1 gene in CSF-1R-expressing cells may facilitate progression of the disease, as has been observed in murine c-myc-induced monocyte/ macrophage
Mutations of c-jhs gene have been reported in myelodysplastic syndromes and Ieukemia? however, their relationship with serum CSF-1 levels has not been investigated. Recent findings of CSF-1 mRNA and c-fms in human lymphoid neoplasic cellsm~z' raise the possibility that CSF-1 may stimulate the growth of these cells in lympheid malignancies. Our correlation of high circulating CSF-1 with an active state of NHL and HD (Table 3) , p2 microglobulin in MM (Table 4) , and blast numbers in AML cases (Fig 4) supports this hypothesis.
However, autocrine stimulation by other cytokines has been postulated in some of these di~orders,4~-~' and the absence of inhibitors of growth may allow the uncontrolled proliferation of neoplastic cells. Therefore, autocrine or paracrine stimulation by CSF-1 should be viewed only as one component in a complex of many positive and negative control elements that, if deregulated, could contribute to malignant proliferation.
Another possible mechanism for the high circulating CSF-1 is decreased catabolism of the factor, which most probably in humans, as in mice, normally is degraded by macrophages of liver and spleen.z These cell compartments could become infiltrated by the malignant cells and the normal cells thereby destroyed. This result is not likely in all cases, however, as the circulating CSF-1 was significantly increased in groups of our patients who had refractory anemia, or others with no involvement of the liver or of the spleen in their neoplastic disease. Given that, normally, circulating CSF-1 is produced by cells other than macrophages, a further possibility is that impaired macrophage function results in decreased clearance of CSF-1 and, thus, its increased circulating levels.
The role of changes in CSF-1 in vivo during neutropenia and neutrophilia remains unclear. Hanamura et aIz reported significantly increased CSF-1 levels in about half of their patients with hematologic malignancy and neutropenia studied after anticancer chemotherapy. The other half apparently had normal CSF-1 levels, a "lack of response" to neutropenia the authors attributed to cytotoxic effects of chemotherapy on cells producing CSF-1. However, as the basal CSF-1 levels were not recorded before chemotherapy, the cause of the high CSF-1 levels recorded during neutropenia is not clear. We observed that in our 75 patients with MDS, some of whom had severe neutropenia, there was no correlation between circulating CSF-1 and leukocyte, monocyte, or neutrophil counts. Thus, the reduction in numbers of peripheral blood leukocytes is not the regulatory mechanism for increased levels of CSF-1 in those disorders. Furthermore, we could find no such correlation in patients NHL, HD, and MM, or between 'on therapy' and 'no therapy' groups. This last finding also indicates that the postuIated damage to CSF-1-producing cells by chemotherapy may not be a significant factor.
The available data are consistent with the elevation of circulating CSF-1 in patients with premalignant and malignant hematologic disorders being due most probably to synthesis by the malignant or premalignant cells themselves or perhaps, in some cases, by normal cells under the control of the malignant or premalignant cells. Further work is necessary to establish the cellular basis for the elevation of CSF-1 in these diseases and the degree to which elevated CSF-1 contributes to the development of malignancy. For personal use only. on September 22, 2017 . by guest www.bloodjournal.org From
